Skip to main content
. 2023 Jan 27;114(4):1297–1308. doi: 10.1111/cas.15720

FIGURE 4.

FIGURE 4

Prognostic model based on DNMT3A R882 mutation/NPM1 mutation/FLT3‐ITD allelic ratio genotypes. (A) Prognostic stratification using NPM1/FLT3‐ITD genotypes (overall survival; OS) according to the European LeukemiaNet 2017 (ELN 2017) classification of NPM1‐mutated acute myeloid leukemia (AML). (B) Prognostic stratification using NPM1/FLT3‐ITD genotypes (OS censored at allo‐HSCT) according to the ELN 2017 classification of NPM1‐mutated AML. (C) Prognostic stratification using NPM1/FLT3‐ITD genotypes (event‐free survival; EFS) according to the ELN 2017 classification of NPM1‐mutated AML. (D) Prognostic stratification using DNMT3AR882/NPM1/FLT3‐ITD genotypes (OS) according to the multicenter collaborative program for gene sequencing of Japanese AML (GS‐JAML) classification of NPM1‐mutated AML. (E) Prognostic stratification using DNMT3AR882/NPM1/FLT3‐ITD genotypes (OS censored at allo‐HSCT) according to the GS‐JAML classification of NPM1‐mutated AML (F) Prognostic stratification using DNMT3AR882/NPM1/FLT3‐ITD genotypes (EFS) according to the GS‐JAML classification of NPM1‐mutated AML